Oncotelic Therapeutics Reports $1.7 Billion Pipeline Valuation from Joint Venture Partner

Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced that joint venture partner GMP Bio has received an independent Frost & Sullivan (Hong Kong) valuation estimating the potential value of its therapeutic pipeline at approximately $1.7 billion. This valuation implies about $765 million for Oncotelic's 45% stake in the joint venture, representing a significant potential increase in the company's asset valuation. The analysis, while non-binding and forward-looking, provides external validation of the therapeutic pipeline's market potential and development progress.

The valuation comes as the joint venture advances OT-101 into Phase 3 trials for pancreatic ductal adenocarcinoma (PDAC) and Phase 2 combination trials, while simultaneously expanding its nanomedicine pipeline through the Deciparticle(TM) platform. CEO Dr. Vuong Trieu stated that the valuation affirms progress across both the OT-101 program and the broader platform technology. The joint venture operates a GMP-licensed facility in San Diego, supporting the development and manufacturing of these therapeutic candidates.

Oncotelic has initiated a separate ASC-compliant valuation that will support future financial reporting, with the company potentially recording a higher carrying value for its minority interest in upcoming periods consistent with applicable fair-value measurement standards. This independent valuation process is crucial for accurate financial reporting and investor transparency. The latest news and updates relating to OTLC are available in the company's newsroom at https://ibn.fm/OTLC.

The joint venture is preparing for a potential Hong Kong IPO in late 2026, subject to market and regulatory conditions. This strategic move could provide additional capital for pipeline development and potentially unlock further value for Oncotelic shareholders. The timing aligns with anticipated clinical milestones across multiple programs, including the advancement of OT-101 through later-stage clinical trials.

This development is particularly significant given that Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company's mission centers on addressing high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. The joint venture structure allows Oncotelic to benefit from a broader portfolio of inventions while maintaining focus on its core development programs.

The valuation announcement represents a key milestone in the company's strategic positioning within the oncology and rare disease therapeutics landscape. For more information about InvestorWire's specialized communications platform, visit https://www.InvestorWire.com. The full terms of use and disclaimers are available at https://www.InvestorWire.com/Disclaimer.